Orgenesis (ORGS:NASDAQ) Investor Relations Material

Overview

Biotech company Orgenesis Inc. has made significant strides in the global cell and gene therapies sector with its innovative Point of Care (POCare) platform. The company's POCare technology system facilitates the development of licensed therapeutics, which are produced using closed automated systems within a collaborative network. With a focus on autologous therapies, Orgenesis tailors its approach to suit each individual therapy, employing validated closed and automated processing systems that comply with industry regulations. The Germantown, Maryland-based company was previously known as Business Outsourcing Service, Inc. before rebranding itself as Orgenesis Inc. in 2011. Founded in 2008, Orgenesis has become a leading contender in the biotech sector with its cutting-edge technology and patient-centric approach.

Frequently Asked Questions

What is Orgenesis's ticker?

Orgenesis's ticker is ORGS

What exchange is Orgenesis traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Orgenesis's headquarters?

They are based in Germantown, Maryland

How many employees does Orgenesis have?

There are 201-500 employees working at Orgenesis

What is Orgenesis's website?

It is orgenesis.com/#

What type of sector is Orgenesis?

Orgenesis is in the Healthcare sector

What type of industry is Orgenesis?

Orgenesis is in the Biotechnology industry

Who are Orgenesis's peers and competitors?

The following five companies are Orgenesis's industry peers:

- Solid Biosciences

- Gemphire Therapeutics Inc

- Deciphera Pharmaceuticals

- Xeris Biopharma Holdings Inc

- AC Immune